Clinical Trials

A listing of current lymphoma clinical trials available at UNC Lineberger Comprehensive Cancer Center.

Diffuse large B-cell lymphoma (DLBCL)

DiseaseStudy #Study Title and DescriptionPI

Relapsed

SGN19A-003A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell TransplantChristopher Dittus, DO, MPH

GO29383

A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered With Obinutuzumab or Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Christopher Dittus, DO, MPH

Hodgkin Lymphoma

DiseaseStudy #Study Title and DescriptionPI
RelapsedLCCC1524-ATLPhase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)Thomas Shea, MD
LCCC1532-ATL Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma Thomas Shea, MD

General Lymphoma

DiseaseStudy #Study Title and DescriptionPI

Relapsed

BMA117159

A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects With Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA Brandi Reeves, MD

 

INCB57643

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies

Catherine Coombs, MD

 

Search for Clinical Trials